Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates

To you the reader, the joy of discovery begins, for We continue in our goal of providing a text which us the job is done. In this edition, we have corrected is useful, not only to the clinician, but of equal interest past deficiencies, added new topics, expanded infor- to the investigator. The selection of content has been mation regarding the pediatric age group, provided directed at topics of current interest rather than those up to date (March 2003) references, while remaining of historic contribution. We have stressed the cont- true to our concept of a multi-national author book. bution of cell biology and pathophysiology, were it We continue to believe that scientific information is an exists, believing it provides both a better understa- international commodity whose interpretation and ap- ing of toxic injury when known, and a rational dir- plication are strongly influenced by both the cultural tion for therapy and prevention. and ethnic background of the observer. The oppor- nity to share in the rich diversity of the international We are encouraged by the accumulation of rec- scientific community remains a fundamental goal of nized risk factors, which allow pre-treatment strati- this endeavor. To participate as equals leads to mu- cation of our patients’ relative risk and allow us to - tual respect and peer appreciation. The sharing of in- cus our preventative techniques on the individuals tellectual resources fostered by this effort should and most likely to gain the greatest benefit.

Developed as a one-stop reference source for drug safety and toxicology professionals, this book explains why mitochondrial failure is a crucial step in drug toxicity and how it can be avoided. • Covers both basic science and applied technology / methods • Allows readers to understand the basis of mitochondrial function, the preclinical assessments used, and what they reveal about drug effects • Contains both in vitro and in vivo methods for analysis, including practical screening approaches for drug discovery and development • Adds coverage about mitochondrial toxicity underlying organ injury, clinical reports on drug classes, and discussion of environmental toxicants affecting mitochondria

L'utilisation d'antibiotiques contenant notamment des aminoglycosides pour com¬battre les affections bactériennes, est très répandue. Or, à long terme, elle pose sou¬vent des complications dont la néphrotoxicité est la plus fréquente. Si les manifes¬tations de ces complications rénales sont connues, les mécanismes de ces altérations le sont moins. Ces communications apportent donc des éclaircissements sur ces mécanismes et les effets de ces substances dans les néphrons, le transport et la pénétration dans les cellules labyrinthiques du rein, l'influence sur la structure cellulaire, les effets au niveau de l'appareil de Colgi et notamment les réactions des organites intracellulaires : lysosomes-mitochendria.

This text offers medical students a case-based approach to learning the mechanisms of renal disease. Each chapter covers a disease, beginning with a patient case and followed by a discussion of the pathophysiology of the disease. Issues of differential diagnosis and therapy are linked to pathophysiologic mechanisms. Short questions interspersed throughout the text require students to apply their knowledge. Detailed answers to the questions are included. New to this edition: Full-color artwork and design New color photomicrographs of clinical conditions Additional end-of-chapter summaries Up-to-date information based on new medical findings

This is the 11th of the Pediatric Nephrology series created to help us be in touch with developments which are relevant to the problems we face daily in clinical practice and the questions we ask and try to answer in clinical and experimental research. Like volume IX, this one focuses on one of the subgroups to which we are committed--the neonates' special fluid and electrolyte requirements. This volume has more on blood pressure and renal function and looks at the hormonal regulators. There is greater depth about intoxications and nephrotic agents, congenital disorders and mineral metabolism. The exchanges were stimulating and the controversies were brought out without need of much of my usual prodding. At Julie Ingelfinger's suggestion, at the end of each panel discussion I have added a comment to highlight the main points as I see them. Otherwise, the format remains as in past editions: the papers given related to the four major topic areas, each followed by panel and registrant discussion. Although the transcription is almost verbatim, you will not find the names of the discussants, purposely omitted to ease my editorial work and to encourage everyone to speak candidly. Some of the questions and answers are those submitted to the panelists after the sessions, incorporated here by request. Also, frequent references are made to others' work but their names have been omitted.

Nephrology is one of the fastest growing specialties in medicine. Nevertheless, kidney disease is one of the most serious unmet health needs in many countries. To provide healthcare access with the desirable equity worldwide, the nephrology community needs to discuss this public health issue and take part in decisions for elaboration of public health policies with more justice and equity. This book brings together key current public health problems that affect kidney function and illuminates them in contributions by an international group of nephrologists and general practitioners. The chapters review current knowledge and provide guidelines to manage these conditions and decrease the disease burden. At the end, developments in the digital era and their application to kidney disease treatment are synthesized, and a broader outlook on the future of nephrology is given. Ultimately, the publication aims to gather nephrology and public health expertise from researchers from all over the world, providing a broad vision of issues that must be discussed and overcome to guarantee a better treatment for patients with kidney diseases in the world today.

There has been a growing awareness that nephrotoxicity represents a key factor in human nephropathies, where, irrespective of the causative agent, only a few clinical end-effects are diagnosed. Thus nephropathies are generally classified as acute or chronic renal failure, malignancies or immunological changes. The weaknesses in diagnosing nephropathies arises because of the effective role the kidney plays in maintaining homeostasis, despite the fact that it has been extensively damaged. The frequencies of some type of chemically-induced acute renal failure is well documented, but the causes of chronic renal failure, malignancy, and other nephropathies are far more difficult to associate with a chemical aetiology. Many of the new therapeutic agents have important beneficial effects, but they are found to have marked nephrotoxic effects. Thus there is a growing urgency to increase the stringency of chemical safety evaluation for their potential nephrotoxic effects. This is strongly countered by the increased financial pressure to identify potentially nephrotoxic chemicals earlier in their development and humanitarian considerations to more closely relate animal test to the clinical situation. Part of the challenge may be achieved by the increasing use of in vitro techniques.